Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 118 entries
Sorted by: Best Match Show Resources per page
Same song, different audience: pharmaceutical promotion targeting non-physician health care providers.

PLoS medicine

Yeh JS, Kesselheim AS.
PMID: 24302891
PLoS Med. 2013 Nov;10(11):e1001560. doi: 10.1371/journal.pmed.1001560. Epub 2013 Nov 26.

No abstract available.

Cite
Yeh JS, Kesselheim AS. Same song, different audience: pharmaceutical promotion targeting non-physician health care providers. PLoS Med. 2013;10(11):e1001560doi: 10.1371/journal.pmed.1001560.
Yeh, J. S., & Kesselheim, A. S. (2013). Same song, different audience: pharmaceutical promotion targeting non-physician health care providers. PLoS medicine, 10(11), e1001560. https://doi.org/10.1371/journal.pmed.1001560
Yeh, James S, and Kesselheim, Aaron S. "Same song, different audience: pharmaceutical promotion targeting non-physician health care providers." PLoS medicine vol. 10,11 (2013): e1001560. doi: https://doi.org/10.1371/journal.pmed.1001560
Yeh JS, Kesselheim AS. Same song, different audience: pharmaceutical promotion targeting non-physician health care providers. PLoS Med. 2013 Nov;10(11):e1001560. doi: 10.1371/journal.pmed.1001560. Epub 2013 Nov 26. PMID: 24302891; PMCID: PMC3841098.
Copy Download .nbib Format: NLM
Defining "True and Non-Misleading" for Pharmaceutical Promotion.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics

Hey SP, Kesselheim AS.
PMID: 30146990
J Law Med Ethics. 2018 Jun;46(2):552-554. doi: 10.1177/1073110518782970.

No abstract available.

Cite
Hey SP, Kesselheim AS. Defining "True and Non-Misleading" for Pharmaceutical Promotion. J Law Med Ethics. 2018;46(2):552-554doi: 10.1177/1073110518782970.
Hey, S. P., & Kesselheim, A. S. (2018). Defining "True and Non-Misleading" for Pharmaceutical Promotion. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 46(2), 552-554. https://doi.org/10.1177/1073110518782970
Hey, Spencer Phillips, and Kesselheim, Aaron S. "Defining "True and Non-Misleading" for Pharmaceutical Promotion." The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics vol. 46,2 (2018): 552-554. doi: https://doi.org/10.1177/1073110518782970
Hey SP, Kesselheim AS. Defining "True and Non-Misleading" for Pharmaceutical Promotion. J Law Med Ethics. 2018 Jun;46(2):552-554. doi: 10.1177/1073110518782970. PMID: 30146990.
Copy Download .nbib Format: NLM
Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012.

JACC. Basic to translational science

Hwang TJ, Lauffenburger JC, Franklin JM, Kesselheim AS.
PMID: 30167520
JACC Basic Transl Sci. 2016 Aug 29;1(5):301-308. doi: 10.1016/j.jacbts.2016.03.012. eCollection 2016 Aug.

Cardiovascular disease remains a leading cause of death, but stakeholders have recently raised concerns about the pace of innovation and investment in developing new therapeutics. Here, the authors characterized temporal trends in cardiovascular research and development over the past...

Cite
Hwang TJ, Lauffenburger JC, Franklin JM, et al. Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. JACC Basic Transl Sci. 2016;1(5):301-308doi: 10.1016/j.jacbts.2016.03.012.
Hwang, T. J., Lauffenburger, J. C., Franklin, J. M., & Kesselheim, A. S. (2016). Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. JACC. Basic to translational science, 1(5), 301-308. https://doi.org/10.1016/j.jacbts.2016.03.012
Hwang, Thomas J, et al. "Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012." JACC. Basic to translational science vol. 1,5 (2016): 301-308. doi: https://doi.org/10.1016/j.jacbts.2016.03.012
Hwang TJ, Lauffenburger JC, Franklin JM, Kesselheim AS. Temporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012. JACC Basic Transl Sci. 2016 Aug 29;1(5):301-308. doi: 10.1016/j.jacbts.2016.03.012. eCollection 2016 Aug. PMID: 30167520; PMCID: PMC6113354.
Copy Download .nbib Format: NLM
Rising to the Challenge: Residency Programs' Experience With Implementing Milestones-Based Assessment.

Journal of graduate medical education

Dzara K, Huth K, Kesselheim JC, Schumacher DJ.
PMID: 31440339
J Grad Med Educ. 2019 Aug;11(4):439-446. doi: 10.4300/JGME-D-18-00717.1.

BACKGROUND: Changes to assessment efforts following the shift to milestones-based assessment in the ACGME Next Accreditation System have not been fully characterized.OBJECTIVE: This study describes themes in initial milestones-based assessment practices with the goal of informing continued implementation and...

Cite
Dzara K, Huth K, Kesselheim JC, et al. Rising to the Challenge: Residency Programs' Experience With Implementing Milestones-Based Assessment. J Grad Med Educ. 2019;11(4):439-446doi: 10.4300/JGME-D-18-00717.1.
Dzara, K., Huth, K., Kesselheim, J. C., & Schumacher, D. J. (2019). Rising to the Challenge: Residency Programs' Experience With Implementing Milestones-Based Assessment. Journal of graduate medical education, 11(4), 439-446. https://doi.org/10.4300/JGME-D-18-00717.1
Dzara, Kristina, et al. "Rising to the Challenge: Residency Programs' Experience With Implementing Milestones-Based Assessment." Journal of graduate medical education vol. 11,4 (2019): 439-446. doi: https://doi.org/10.4300/JGME-D-18-00717.1
Dzara K, Huth K, Kesselheim JC, Schumacher DJ. Rising to the Challenge: Residency Programs' Experience With Implementing Milestones-Based Assessment. J Grad Med Educ. 2019 Aug;11(4):439-446. doi: 10.4300/JGME-D-18-00717.1. PMID: 31440339; PMCID: PMC6699530.
Copy Download .nbib Format: NLM
Addressing implicit bias in pediatric hematology-oncology.

Pediatric blood & cancer

Tsai JW, Kesselheim JC.
PMID: 32159300
Pediatr Blood Cancer. 2020 May;67(5):e28204. doi: 10.1002/pbc.28204. Epub 2020 Mar 11.

Although awareness of implicit bias and its influence on providers and patients is increasing, the effects of implicit bias on the field of pediatric hematology-oncology are less clear. This Special Report reviews the literature on implicit bias in pediatrics...

Cite
Tsai JW, Kesselheim JC. Addressing implicit bias in pediatric hematology-oncology. Pediatr Blood Cancer. 2020;67(5):e28204doi: 10.1002/pbc.28204.
Tsai, J. W., & Kesselheim, J. C. (2020). Addressing implicit bias in pediatric hematology-oncology. Pediatric blood & cancer, 67(5), e28204. https://doi.org/10.1002/pbc.28204
Tsai, Jessica W, and Kesselheim, Jennifer C. "Addressing implicit bias in pediatric hematology-oncology." Pediatric blood & cancer vol. 67,5 (2020): e28204. doi: https://doi.org/10.1002/pbc.28204
Tsai JW, Kesselheim JC. Addressing implicit bias in pediatric hematology-oncology. Pediatr Blood Cancer. 2020 May;67(5):e28204. doi: 10.1002/pbc.28204. Epub 2020 Mar 11. PMID: 32159300.
Copy Download .nbib Format: NLM
Incentivizing Antibiotic Development: Why Isn't the Generating Antibiotic Incentives Now (GAIN) Act Working?.

Open forum infectious diseases

Darrow JJ, Kesselheim AS.
PMID: 32016125
Open Forum Infect Dis. 2020 Jan 28;7(1):ofaa001. doi: 10.1093/ofid/ofaa001. eCollection 2020 Jan.

Antimicrobial resistance is of increasing global concern. To incentivize the creation of new treatments, the US Congress enacted the Generating Antibiotic Incentives Now Act (GAIN Act) of 2012, which provides benefits to manufacturers of Qualified Infectious Disease Products (QIDPs)...

Cite
Darrow JJ, Kesselheim AS. Incentivizing Antibiotic Development: Why Isn't the Generating Antibiotic Incentives Now (GAIN) Act Working?. Open Forum Infect Dis. 2020;7(1):ofaa001doi: 10.1093/ofid/ofaa001.
Darrow, J. J., & Kesselheim, A. S. (2020). Incentivizing Antibiotic Development: Why Isn't the Generating Antibiotic Incentives Now (GAIN) Act Working?. Open forum infectious diseases, 7(1), ofaa001. https://doi.org/10.1093/ofid/ofaa001
Darrow, Jonathan J, and Kesselheim, Aaron S. "Incentivizing Antibiotic Development: Why Isn't the Generating Antibiotic Incentives Now (GAIN) Act Working?." Open forum infectious diseases vol. 7,1 (2020): ofaa001. doi: https://doi.org/10.1093/ofid/ofaa001
Darrow JJ, Kesselheim AS. Incentivizing Antibiotic Development: Why Isn't the Generating Antibiotic Incentives Now (GAIN) Act Working?. Open Forum Infect Dis. 2020 Jan 28;7(1):ofaa001. doi: 10.1093/ofid/ofaa001. eCollection 2020 Jan. PMID: 32016125; PMCID: PMC6986775.
Copy Download .nbib Format: NLM
Current Fellowship Funding Limitations and Their Threat to the Pediatric Subspecialty Workforce.

Academic pediatrics

Weiss P, Myers AL, McGann KA, Kesselheim JC, Barron C, Klasner A, Heyman MB, Weiss DL, Mauer E, Mason KE, Gerber LM, Abramson EL.
PMID: 34389517
Acad Pediatr. 2021 Nov-Dec;21(8):1328-1330. doi: 10.1016/j.acap.2021.08.006. Epub 2021 Aug 10.

No abstract available.

Cite
Weiss P, Myers AL, McGann KA, et al. Current Fellowship Funding Limitations and Their Threat to the Pediatric Subspecialty Workforce. Acad Pediatr. 2021;21(8):1328-1330doi: 10.1016/j.acap.2021.08.006.
Weiss, P., Myers, A. L., McGann, K. A., Kesselheim, J. C., Barron, C., Klasner, A., Heyman, M. B., Weiss, D. L., Mauer, E., Mason, K. E., Gerber, L. M., & Abramson, E. L. (2021). Current Fellowship Funding Limitations and Their Threat to the Pediatric Subspecialty Workforce. Academic pediatrics, 21(8), 1328-1330. https://doi.org/10.1016/j.acap.2021.08.006
Weiss, Pnina, et al. "Current Fellowship Funding Limitations and Their Threat to the Pediatric Subspecialty Workforce." Academic pediatrics vol. 21,8 (2021): 1328-1330. doi: https://doi.org/10.1016/j.acap.2021.08.006
Weiss P, Myers AL, McGann KA, Kesselheim JC, Barron C, Klasner A, Heyman MB, Weiss DL, Mauer E, Mason KE, Gerber LM, Abramson EL. Current Fellowship Funding Limitations and Their Threat to the Pediatric Subspecialty Workforce. Acad Pediatr. 2021 Nov-Dec;21(8):1328-1330. doi: 10.1016/j.acap.2021.08.006. Epub 2021 Aug 10. PMID: 34389517.
Copy Download .nbib Format: NLM
Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Rome BN, Lee CC, Gagne JJ, Kesselheim AS.
PMID: 34119078
Value Health. 2021 Jun;24(6):804-811. doi: 10.1016/j.jval.2020.12.020. Epub 2021 Apr 22.

OBJECTIVES: In the United States, brand-name prescription drugs remain expensive until market exclusivity ends and lower-cost generics become available. Delayed generic drug uptake may increase spending and worsen medication adherence and patient outcomes. We assessed recent trends and factors...

Cite
Rome BN, Lee CC, Gagne JJ, et al. Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017. Value Health. 2021;24(6):804-811doi: 10.1016/j.jval.2020.12.020.
Rome, B. N., Lee, C. C., Gagne, J. J., & Kesselheim, A. S. (2021). Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 24(6), 804-811. https://doi.org/10.1016/j.jval.2020.12.020
Rome, Benjamin N, et al. "Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 24,6 (2021): 804-811. doi: https://doi.org/10.1016/j.jval.2020.12.020
Rome BN, Lee CC, Gagne JJ, Kesselheim AS. Factors Associated With Generic Drug Uptake in the United States, 2012 to 2017. Value Health. 2021 Jun;24(6):804-811. doi: 10.1016/j.jval.2020.12.020. Epub 2021 Apr 22. PMID: 34119078.
Copy Download .nbib Format: NLM
Leveraging Podcasts to Introduce Medical Students to the Broader Community of Health Care Professionals.

MedEdPORTAL : the journal of teaching and learning resources

Miller KA, Keeney T, Fialkowski A, Srinivasan S, Singh TA, Kesselheim J, Farrell S, Cooper C, Royce CS.
PMID: 34754938
MedEdPORTAL. 2021 Oct 25;17:11191. doi: 10.15766/mep_2374-8265.11191. eCollection 2021.

INTRODUCTION: Safe, patient-centered, and cost-effective care requires effective collaboration within interprofessional teams. Education programs for health care professionals are often siloed, providing students with limited interprofessional education (IPE) opportunities to learn from, with, and about other professions. Podcasts offer...

Cite
Miller KA, Keeney T, Fialkowski A, et al. Leveraging Podcasts to Introduce Medical Students to the Broader Community of Health Care Professionals. MedEdPORTAL. 2021;17:11191doi: 10.15766/mep_2374-8265.11191.
Miller, K. A., Keeney, T., Fialkowski, A., Srinivasan, S., Singh, T. A., Kesselheim, J., Farrell, S., Cooper, C., & Royce, C. S. (2021). Leveraging Podcasts to Introduce Medical Students to the Broader Community of Health Care Professionals. MedEdPORTAL : the journal of teaching and learning resources, 1711191. https://doi.org/10.15766/mep_2374-8265.11191
Miller, Kelsey A, et al. "Leveraging Podcasts to Introduce Medical Students to the Broader Community of Health Care Professionals." MedEdPORTAL : the journal of teaching and learning resources vol. 17 (2021): 11191. doi: https://doi.org/10.15766/mep_2374-8265.11191
Miller KA, Keeney T, Fialkowski A, Srinivasan S, Singh TA, Kesselheim J, Farrell S, Cooper C, Royce CS. Leveraging Podcasts to Introduce Medical Students to the Broader Community of Health Care Professionals. MedEdPORTAL. 2021 Oct 25;17:11191. doi: 10.15766/mep_2374-8265.11191. eCollection 2021. PMID: 34754938; PMCID: PMC8542682.
Copy Download .nbib Format: NLM
Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015.

JAMA network open

Khorrami P, Sinha MS, Bhanja A, Allen HL, Kesselheim AS, Sommers BD.
PMID: 35029667
JAMA Netw Open. 2022 Jan 04;5(1):e2140371. doi: 10.1001/jamanetworkopen.2021.40371.

IMPORTANCE: Increasing prices of antidiabetic medications in the US have raised substantial concerns about the effects of drug affordability on diabetes care. There has been little rigorous evidence comparing the experiences of patients with diabetes across different types of...

Cite
Khorrami P, Sinha MS, Bhanja A, et al. Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015. JAMA Netw Open. 2022;5(1):e2140371doi: 10.1001/jamanetworkopen.2021.40371.
Khorrami, P., Sinha, M. S., Bhanja, A., Allen, H. L., Kesselheim, A. S., & Sommers, B. D. (2022). Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015. JAMA network open, 5(1), e2140371. https://doi.org/10.1001/jamanetworkopen.2021.40371
Khorrami, Peggah, et al. "Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015." JAMA network open vol. 5,1 (2022): e2140371. doi: https://doi.org/10.1001/jamanetworkopen.2021.40371
Khorrami P, Sinha MS, Bhanja A, Allen HL, Kesselheim AS, Sommers BD. Differences in Diabetic Prescription Drug Utilization and Costs Among Patients With Diabetes Enrolled in Colorado Marketplace and Medicaid Plans, 2014-2015. JAMA Netw Open. 2022 Jan 04;5(1):e2140371. doi: 10.1001/jamanetworkopen.2021.40371. PMID: 35029667.
Copy Download .nbib Format: NLM
US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines.

Clinical pharmacology and therapeutics

Lalani HS, Avorn J, Kesselheim AS.
PMID: 34243221
Clin Pharmacol Ther. 2021 Jul 09; doi: 10.1002/cpt.2344. Epub 2021 Jul 09.

No abstract available.

Cite
Lalani HS, Avorn J, Kesselheim AS. US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines. Clin Pharmacol Ther. 2021;doi: 10.1002/cpt.2344.
Lalani, H. S., Avorn, J., & Kesselheim, A. S. (2021). US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines. Clinical pharmacology and therapeutics, . https://doi.org/10.1002/cpt.2344
Lalani, Hussain S, et al. "US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines." Clinical pharmacology and therapeutics vol. (2021). doi: https://doi.org/10.1002/cpt.2344
Lalani HS, Avorn J, Kesselheim AS. US Taxpayers Heavily Funded the Discovery of COVID-19 Vaccines. Clin Pharmacol Ther. 2021 Jul 09; doi: 10.1002/cpt.2344. Epub 2021 Jul 09. PMID: 34243221; PMCID: PMC8426978.
Copy Download .nbib Format: NLM
Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases.

Journal of health politics, policy and law

Liu S, Mello MM, Kesselheim AS.
PMID: 33647951
J Health Polit Policy Law. 2021 Jun 01;46(3):487-504. doi: 10.1215/03616878-8893571.

CONTEXT: Food and Drug Administration (FDA) rules restrict pharmaceutical manufacturers from promoting drugs for non-FDA-approved (off-label) indications. When manufacturers violate this rule, it has in many cases led to unsafe prescribing. However, in 2012, a federal circuit court ruled...

Cite
Liu S, Mello MM, Kesselheim AS. Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases. J Health Polit Policy Law. 2021;46(3):487-504doi: 10.1215/03616878-8893571.
Liu, S., Mello, M. M., & Kesselheim, A. S. (2021). Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases. Journal of health politics, policy and law, 46(3), 487-504. https://doi.org/10.1215/03616878-8893571
Liu, Sheng, et al. "Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases." Journal of health politics, policy and law vol. 46,3 (2021): 487-504. doi: https://doi.org/10.1215/03616878-8893571
Liu S, Mello MM, Kesselheim AS. Prospects for Enforcing Prohibitions on Off-Label Drug Promotion after United States v. Caronia: An Analysis of Litigated Cases. J Health Polit Policy Law. 2021 Jun 01;46(3):487-504. doi: 10.1215/03616878-8893571. PMID: 33647951.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 118 entries